What insurance policy changes affect code K12.0?

There are 6 tracked policy changes affecting code K12.0, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code K12.0?

Payers that have issued tracked updates for code K12.0 include: Aetna.

How do I get notified when code K12.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code K12.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code K12.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

K12.0 Insurance Policy Changes

ICD-10 K12.0 is officially defined as "Recurrent oral aphthae." code K12.0 is referenced in 6 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code K12.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 23, 2026Medium impact
Oral and Esophageal Brush Biopsy (CPB 0686, reviewed 2026-10-15)
Aetna Clinical Policy Bulletin 0686 on oral and esophageal brush biopsy was last reviewed on 10/15/2026. It considers oral brush biopsy (OralCDx) with or without MAGE-A or GLUT-1 staining, esophageal brush biopsy (WATS3D, formerly EndoCDx), DNA-image cytometry, RNA-based oral brush biopsy, salivary miRNAs and esophageal balloon cytologic sampling experimental, investigational or unproven because their effectiveness has not been established, for screening, diagnosis or surveillance. The policy lists CPT 88104 and 99000, HCPCS D0486 and D7288, and several ICD-10 codes, including Z12.81, as not covered for the indications it lists.
Aetna · Identified Aug 19, 2026Medium impact
YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)
Aetna considers Nd:YAG laser capsulotomy medically necessary after cataract extraction in members with visually significant clouding of the posterior capsule, and considers Nd:YAG laser peripheral iridotomy medically necessary for acute primary angle closure, primary angle-closure glaucoma, plateau iris syndrome, aqueous misdirection, and before intraocular lens insertion into the anterior chamber to avoid post-operative iris bombe or pupil block. Capsulotomy performed within 6 months of cataract surgery is subject to medical necessity review, and it is considered experimental, investigational, or unproven if none of the stated criteria is met. Nd:YAG laser vitreolysis for vitreous floaters, posterior hyaloidotomy for pre-macular hemorrhage, goniopuncture for failed trabeculectomy, and peripheral iridotomy to prevent pigment dispersion glaucoma are considered experimental, investigational, or unproven, as are many non-ophthalmological uses such as basal cell carcinoma, benign prostatic hyperplasia, onychomycosis and snoring.
Aetna · Identified Aug 17, 2026Medium impact
Helicobacter Pylori Infection Testing (CPB 0177, reviewed 2026-03-20)
Aetna considers FDA-cleared carbon isotope (13C or 14C) urea breath testing and stool antigen testing (HpSA) medically necessary for active Helicobacter pylori infection in selected persons, including adults with idiopathic thrombocytopenic purpura, persons before bariatric surgery, persons before starting proton pump inhibitor therapy for dyspepsia, and persons taking long term, low-dose aspirin or initiating chronic NSAID treatment. Nucleic acid amplification for clarithromycin resistance testing is medically necessary for selecting salvage regimens for treatment-experienced individuals with persistent H. pylori infection. H. pylori serology, the AmHPR panel, IL-1B and TNFA gene polymorphism testing, and urea breath or stool antigen testing for other indications such as stroke risk, dementia risk and screening of asymptomatic persons are considered experimental, investigational or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Complementary and Alternative Medicine (CPB 0388, reviewed 2026-06-25)
Aetna covers alternative medicine interventions when they are supported by adequate evidence of safety and effectiveness in the peer-reviewed published medical literature, subject to benefit plan limitations and exclusions. Acupuncture, biofeedback, chelation therapy, chiropractic services and electrical stimulation are addressed under separate Aetna policies. Many other interventions are listed as experimental, investigational or unproven, including intravenous micronutrient therapy (Myers' Cocktail), Gua Sha, colon hydrotherapy and the Patricia Kane protocol, and standard benefit plans exclude nutritional supplements and medical marijuana.
Aetna · Identified Aug 15, 2026Medium impact
Carbon Dioxide Laser (CPB 0427, reviewed 2026-07-08)
Aetna's clinical policy bulletin for carbon dioxide laser (CPB 0427) lists the uses it considers medically necessary: condyloma, pelvic pain associated with endometriosis, primary penile tumors (clinical stage Tis, Ta, and T1 Grade 1 to 2), refractory plantar warts, removal of actinic keratoses for members who meet CPB 0567 criteria, removal of superficial basal cell carcinomas, and fractional carbon dioxide laser for hypertrophic burn, traumatic, and surgical scars when conventional therapies have failed. Aetna considers carbon dioxide laser experimental, investigational, or unproven for a list of other indications, including hidradenitis suppurativa, male androgenetic alopecia, onychomycosis, port wine stains, stress urinary incontinence, and vaginal atrophy. Aetna considers carbon dioxide laser treatment of other actinic lesions cosmetic.
Aetna · Identified Aug 12, 2026Medium impact
Oral and Esophageal Brush Biopsy (CPB 0686, reviewed 2025-10-15)
Aetna considers oral brush biopsy (OralCDx Brush Test), with or without MAGE-A or GLUT-1 staining, experimental, investigational or unproven for screening, diagnosis or surveillance of cancerous or pre-cancerous oral lesions. The same designation applies to esophageal brush biopsy with WATS3D (formerly EndoCDx) for screening, diagnosis or surveillance of cancerous or pre-cancerous esophageal lesions, to DNA-image cytometry of brush biopsies for early detection of oral malignancy, to RNA-based oral brush biopsy, to salivary miRNAs as liquid biopsy biomarkers for oropharyngeal squamous cell carcinoma, and to use of an esophageal balloon for circumferential esophageal cytologic sampling. The policy lists CPT 88104 and 99000 and HCPCS D0486 and D7288 among codes not covered for the indications it lists.

Watch K12.0

Get one email when a payer policy names K12.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Oral and Esophageal Brush Biopsy (CPB 0686, reviewed 2026-10-15)

YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)

Helicobacter Pylori Infection Testing (CPB 0177, reviewed 2026-03-20)

Complementary and Alternative Medicine (CPB 0388, reviewed 2026-06-25)

Carbon Dioxide Laser (CPB 0427, reviewed 2026-07-08)

Oral and Esophageal Brush Biopsy (CPB 0686, reviewed 2025-10-15)

What insurance policy changes affect code K12.0?

Which payers have updated policy for code K12.0?

How do I get notified when code K12.0 policy changes?

Why do payers change policies for code K12.0?